Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.
[severe combined immunodeficiency]
Rituximab
(
RTX
)
,
a
chimeric
IgG
1
monoclonal
antibody
directed
against
the
CD
2
0
antigen
,
has
revolutionized
the
treatment
of
B-
cell
malignancies
.
Nevertheless
,
the
relapsed
/
refractory
rates
are
still
high
.
One
strategy
to
increase
the
clinical
effectiveness
of
RTX
is
based
on
antibody-cytokine
fusion
protein
(
immunocytokine
;
ICK
)
vectorizing
together
at
the
tumor
site
the
antibody
effector
activities
and
the
cytokine
co
-signal
required
for
the
generation
of
cytotoxic
cellular
immunity
.
Such
ICKs
linking
various
antibody
formats
to
interleukin
(
IL
)
-
2
are
currently
being
investigated
in
clinical
trials
and
have
shown
promising
results
in
cancer
therapies
.
IL
-
15
,
a
structurally-related
cytokine
,
is
now
considered
as
having
a
better
potential
than
IL
-
2
in
antitumor
immunotherapeutic
strategies
.
We
have
previously
engineered
the
fusion
protein
RLI
,
linking
a
soluble
form
of
human
IL
-
15
Rα-sushi
+
domain
to
human
IL
-
15
.
Compared
with
IL
-
15
,
RLI
displayed
better
biological
activities
in
vitro
and
higher
antitumor
effects
in
vivo
in
murine
and
human
cancer
models
.
In
this
study
,
we
investigated
the
advantages
of
fusing
RLI
to
RTX
.
Anti-
CD
2
0
-
RLI
kept
its
binding
capacity
to
CD
2
0
,
CD
16
and
IL
-
15
receptor
and
therefore
fully
retained
both
antibody
effector
functions
(
ADCC
and
CDC
)
,
and
the
cytokine
potential
of
RLI
.
In
a
severe
combined
immunodeficiency
(
SCID
)
mouse
model
of
disseminated
residual
lymphoma
,
anti-
CD
2
0
-
RLI
was
found
to
induce
long
-term
survival
of
90
%
of
mice
up
to
at
least
120
days
whereas
RLI
and
RTX
,
alone
or
in
combination
,
just
delayed
the
disease
onset
(
100
%
of
death
at
28
,
40
and
51
days
respectively
)
.
These
findings
suggest
that
such
ICK
could
improve
the
clinical
efficacy
of
RTX
,
particularly
in
patients
with
refractory
B-
cell
lymphoma
.
Diseases
Validation
Diseases presenting
"lymphoma"
symptom
adrenal incidentaloma
alpha-thalassemia
carcinoma of the gallbladder
cushing syndrome
dedifferentiated liposarcoma
erdheim-chester disease
erythropoietic protoporphyria
esophageal adenocarcinoma
esophageal carcinoma
familial hypocalciuric hypercalcemia
focal myositis
hirschsprung disease
hodgkin lymphoma, classical
kabuki syndrome
liposarcoma
locked-in syndrome
monosomy 21
oculocutaneous albinism
primary effusion lymphoma
severe combined immunodeficiency
systemic capillary leak syndrome
waldenström macroglobulinemia
wiskott-aldrich syndrome
This symptom has already been validated